rs9263726 is a specific genetic marker for allopurinol-induced severe cutaneous adverse reactions in Chinese patients

被引：5

作者：

Chen, Zhiyao ^{[1
]}

Zhang, Shichao ^{[1
,2
]}

Zhang, Jingjing ^{[1
]}

Zhang, Yan ^{[1
]}

Xue, Ling ^{[1
]}

Miao, Liyan ^{[1
]}

机构：

[1] Soochow Univ, Res Lab, Dept Clin Pharmacol, Affiliated Hosp 1, Suzhou 215006, Peoples R China

[2] Soochow Univ, Coll Pharmaceut Sci, Suzhou 215006, Peoples R China

来源：

PERSONALIZED MEDICINE | 2015年 / 12卷 / 06期

基金：

中国国家自然科学基金;

关键词：

allopurinol; Chinese patients; HLA-B*58:01; rs9263726; SCARs; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; INFLAMMATORY-BOWEL-DISEASE; DRUG-REACTIONS; HAN CHINESE; HYPERURICEMIA; GOUT; FEBUXOSTAT; GUIDELINES; MANAGEMENT;

D O I：

10.2217/pme.15.38

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aim: Screening of an easily detectable biomarker to replace the HLA allele B variant (HLA-B*58:01) testing for predicting allopurinol-induced severe cutaneous adverse reactions (SCARs) in eastern Chinese patients. Methods: Six SNPs and the HLA-B*58:01 were analyzed in 17 patients with allopurinol-induced SCARs and in 151 control patients. SNPs were analyzed by pyrosequencing, and HLA-B*58:01 was evaluated by sequencing-based techniques. Consistency between sequencing-based HLA-B*58:01 testing and pyrosequencing-based rs9263726 testing was investigated in 262 individuals. Results: A significant association with allopurinol-induced SCARs was found at rs9263726 (odds ratio: 108.8) and HLA-B*58:01 (odds ratio: 108.8). The kappa values between sequencing-based HLA-B*58:01 testing and pyrosequencing-based rs9263726 testing were 0.96 (>0.75), demonstrating they were well coincident with each other. Conclusion: rs9263726 was a useful surrogate of HLA-B*58:01 testing for prescreening allopurinol-induced SCARs in eastern Chinese patients.

引用

页码：585 / 592

页数：8

共 27 条

[1] Pharmacogenetics of cutaneous adverse drug reactions
Aihara, Michiko
[J]. JOURNAL OF DERMATOLOGY, 2011, 38 (03) : 246 - 254
[2] CLINICAL CLASSIFICATION OF CASES OF TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME, AND ERYTHEMA MULTIFORME
BASTUJIGARIN, S
RZANY, B
STERN, RS
SHEAR, NH
NALDI, L
ROUJEAU, JC
[J]. ARCHIVES OF DERMATOLOGY, 1993, 129 (01) : 92 - 96
[3] Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
Bisht, Manisha
Bist, S. S.
[J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 73 (06) : 597 - 600
[4] Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout
Bruce, Susan P.
[J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (12) : 2187 - 2194
[5] HLA-B☆58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study
Cheng, L.
Xiong, Y.
Qin, C. Z.
Zhang, W.
Chen, X. P.
Li, J. .
Zhou, H. H.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (02) : 555 - 558
[6] Association between HLA-B☆58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong
Chiu, M. L. S.
Hu, M.
Ng, M. H. L.
Yeung, C. K.
Chan, J. C-Y.
Chang, M. M.
Cheng, S. H.
Li, L.
Tomlinson, B.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (01) : 44 - 49
[7] Assessment and Management of Low Bone Density in Inflammatory Bowel Disease and Performance of Professional Society Guidelines
Etzel, Jason P.
Larson, Meaghan F.
Anawalt, Bradley D.
Collins, Judith
Dominitz, Jason A.
[J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 (10) : 2122 - 2129
[8] French LE, 2006, ALLERGOL INT, V55, P9
[9] Hyperuricemia, gout and the kidney
Gibson, Terence
[J]. CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (02) : 127 - 131
[10] Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing
Hershfield, M. S.
Callaghan, J. T.
Tassaneeyakul, W.
Mushiroda, T.
Thorn, C. F.
Klein, T. E.
Lee, M. T. M.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (02) : 153 - 158

← 1 2 3 →